277 related articles for article (PubMed ID: 27128679)
1. Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.
Mori S; Hidaka M; Kawakita T; Hidaka T; Tsuda H; Yoshitama T; Migita K; Ueki Y
PLoS One; 2016; 11(4):e0154744. PubMed ID: 27128679
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients.
Kivity S; Zafrir Y; Loebstein R; Pauzner R; Mouallem M; Mayan H
Autoimmun Rev; 2014 Nov; 13(11):1109-13. PubMed ID: 25172240
[TBL] [Abstract][Full Text] [Related]
3. Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis.
Calvo-Romero JM
Ann Pharmacother; 2001 Dec; 35(12):1575-7. PubMed ID: 11793624
[TBL] [Abstract][Full Text] [Related]
4. Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.
Vanni KMM; Lyu H; Solomon DH
Rheumatology (Oxford); 2020 Apr; 59(4):709-717. PubMed ID: 31504937
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis.
White DH; Chapman PT; O'Donnell JL; James J; Frampton C; Stamp LK
Intern Med J; 2010 Aug; 40(8):561-5. PubMed ID: 19811562
[TBL] [Abstract][Full Text] [Related]
6. [Toxicity of low-dose methotrexate in rheumatoid arthritis--clinical characteristics in patients with MTX-induced pancytopenia and interstitial pneumonitis].
Ohosone Y; Okano Y; Kameda H; Hama N; Matsumura M; Nojima T; Nakamura K; Kuwana M; Ogasawara T; Hirakata M; Yoshida T; Mimori T; Akizuki M; Ikeda Y
Ryumachi; 1997 Feb; 37(1):16-23. PubMed ID: 9128419
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.
Hoekstra M; van Ede AE; Haagsma CJ; van de Laar MA; Huizinga TW; Kruijsen MW; Laan RF
Ann Rheum Dis; 2003 May; 62(5):423-6. PubMed ID: 12695153
[TBL] [Abstract][Full Text] [Related]
8. A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency.
Park GT; Jeon DW; Roh KH; Mun HS; Lee CH; Park CH; Kang KW; Kim SM; Kang JM; Park HC
Korean J Intern Med; 1999 Jan; 14(1):85-7. PubMed ID: 10063319
[TBL] [Abstract][Full Text] [Related]
9. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?
Cansu DÜ; Teke HÜ; Bodakçi E; Korkmaz C
Clin Rheumatol; 2018 Dec; 37(12):3419-3425. PubMed ID: 30056523
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).
Dhir V; Sandhu A; Kaur J; Pinto B; Kumar P; Kaur P; Gupta N; Sood A; Sharma A; Sharma S
Arthritis Res Ther; 2015 Jun; 17(1):156. PubMed ID: 26063325
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-induced pancytopenia: a case series of 46 patients.
Ajmani S; Preet Singh Y; Prasad S; Chowdhury A; Aggarwal A; Lawrence A; Misra R; Mishra R; Agarwal V
Int J Rheum Dis; 2017 Jul; 20(7):846-851. PubMed ID: 28261918
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
[TBL] [Abstract][Full Text] [Related]
13. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Ortiz Z; Shea B; Suarez Almazor M; Moher D; Wells G; Tugwell P
Cochrane Database Syst Rev; 2000; (2):CD000951. PubMed ID: 10796393
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary function in patients receiving long-term low-dose methotrexate.
Cottin V; Tébib J; Massonnet B; Souquet PJ; Bernard JP
Chest; 1996 Apr; 109(4):933-8. PubMed ID: 8635373
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years.
Lim AY; Gaffney K; Scott DG
Rheumatology (Oxford); 2005 Aug; 44(8):1051-5. PubMed ID: 15901903
[TBL] [Abstract][Full Text] [Related]
16. [Pancytopenia and Pneumocystis carinii pneumonia associated with low dose methotrexate pulse therapy for rheumatoid arthritis--case report and review of literature].
Kitsuwa S; Matsunaga K; Kawai M; Tsuzi T; Kato K; Tani K; Okubo T
Ryumachi; 1996 Jun; 36(3):551-8. PubMed ID: 8779792
[TBL] [Abstract][Full Text] [Related]
17. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.
de Rotte MC; de Jong PH; Pluijm SM; Calasan MB; Barendregt PJ; van Zeben D; van der Lubbe PA; de Sonnaville PB; Lindemans J; Hazes JM; de Jonge R
Arthritis Rheum; 2013 Nov; 65(11):2803-13. PubMed ID: 24166792
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
Kent PD; Luthra HS; Michet C
J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
Gilani ST; Khan DA; Khan FA; Ahmed M
J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
[TBL] [Abstract][Full Text] [Related]
20. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Ghogomu ET; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
J Rheumatol; 2014 Jun; 41(6):1049-60. PubMed ID: 24737913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
